JPWO2021262562A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021262562A5 JPWO2021262562A5 JP2022578934A JP2022578934A JPWO2021262562A5 JP WO2021262562 A5 JPWO2021262562 A5 JP WO2021262562A5 JP 2022578934 A JP2022578934 A JP 2022578934A JP 2022578934 A JP2022578934 A JP 2022578934A JP WO2021262562 A5 JPWO2021262562 A5 JP WO2021262562A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human patient
- acceptable salt
- pembrolizumab
- hif
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 13
- 229940124060 PD-1 antagonist Drugs 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 11
- 229960002621 pembrolizumab Drugs 0.000 claims 11
- LOMMPXLFBTZENJ-ZACQAIPSSA-N F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C=1)F)S(=O)(=O)C)O Chemical group F[C@H]1[C@H](C2=C(C=CC(=C2[C@H]1F)OC=1C=C(C#N)C=C(C=1)F)S(=O)(=O)C)O LOMMPXLFBTZENJ-ZACQAIPSSA-N 0.000 claims 10
- 229940070199 belzutifan Drugs 0.000 claims 10
- 229960003784 lenvatinib Drugs 0.000 claims 9
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000009885 systemic effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000003850 cellular structure Anatomy 0.000 claims 2
- 229960001429 lenvatinib mesylate Drugs 0.000 claims 1
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical group CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042225P | 2020-06-22 | 2020-06-22 | |
| US63/042,225 | 2020-06-22 | ||
| US202163146926P | 2021-02-08 | 2021-02-08 | |
| US63/146,926 | 2021-02-08 | ||
| PCT/US2021/038171 WO2021262562A2 (fr) | 2020-06-17 | 2021-06-21 | Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531930A JP2023531930A (ja) | 2023-07-26 |
| JPWO2021262562A5 true JPWO2021262562A5 (fr) | 2024-06-27 |
Family
ID=85173740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578934A Pending JP2023531930A (ja) | 2020-06-22 | 2021-06-21 | ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230250182A1 (fr) |
| JP (1) | JP2023531930A (fr) |
| KR (1) | KR20230026492A (fr) |
| BR (1) | BR112022026086A2 (fr) |
| CA (1) | CA3183862A1 (fr) |
| MX (1) | MX2022016410A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116063211B (zh) * | 2023-02-14 | 2023-11-10 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种Belzutifan的制备方法 |
-
2021
- 2021-06-21 CA CA3183862A patent/CA3183862A1/fr active Pending
- 2021-06-21 BR BR112022026086A patent/BR112022026086A2/pt unknown
- 2021-06-21 KR KR1020237002564A patent/KR20230026492A/ko active Search and Examination
- 2021-06-21 JP JP2022578934A patent/JP2023531930A/ja active Pending
- 2021-06-21 US US18/009,109 patent/US20230250182A1/en active Pending
- 2021-06-21 MX MX2022016410A patent/MX2022016410A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (fr) | ||
| JP2019503365A5 (fr) | ||
| JP2022191257A5 (fr) | ||
| JP2021098728A5 (fr) | ||
| JP2015512406A5 (fr) | ||
| JP2009517411A5 (fr) | ||
| JP2014516942A5 (fr) | ||
| JP2017528507A5 (fr) | ||
| JP2020508338A5 (fr) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2004531549A5 (fr) | ||
| JP2019533660A5 (fr) | ||
| JPWO2021121367A5 (fr) | ||
| JP2002528502A5 (fr) | ||
| JP2021073257A5 (fr) | ||
| JP2023116697A5 (fr) | ||
| JP2015522077A5 (fr) | ||
| JP2017514911A5 (fr) | ||
| JP2019507786A5 (fr) | ||
| JP2008533079A5 (fr) | ||
| JP2005512946A5 (fr) | ||
| WO2017148129A1 (fr) | Composition pharmaceutique destinée au traitement de la cachexie et son utilisation | |
| JP2002326936A5 (fr) | ||
| JPWO2021262562A5 (fr) | ||
| JP2021503448A5 (fr) |